GERON CORP APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GERON CORP (GERN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $26.66 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-03-02
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $5.77M.
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $6.74M, a 2.15% decline year-over-year.
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $6.74M, a 46.63% decline year-over-year.
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $7.41M, a 51.90% increase year-over-year.
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $26.66M, a 16.50% decline from fiscal 2024.
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $31.93M, a 72.34% increase from fiscal 2023.
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $18.53M, a 131.55% increase from fiscal 2022.
- GERON CORP apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $8.00M, a 0.98% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.77M derived: 10-K 12 month − 3 quarters · filed 2026-03-02 | $12.51M derived: sum of 2 quarters · filed 2026-03-02 | $19.25M derived: sum of 3 quarters · filed 2026-03-02 | $26.66M 10-K · filed 2026-03-02 |
| 2025-09-30 | $6.74M 10-Q · filed 2025-11-07 | $13.48M derived: sum of 2 quarters · filed 2025-11-07 | $20.89M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2025-06-30 | $6.74M 10-Q · filed 2025-11-07 | $14.15M derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2025-03-31 | $7.41M 10-Q · filed 2025-11-07 | |||
| 2024-12-31 | $31.93M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $6.89M 10-Q · filed 2025-11-07 | $19.52M derived: sum of 2 quarters · filed 2025-11-07 | $24.39M derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $12.63M 10-Q · filed 2025-11-07 | $17.50M derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | $4.88M 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $18.53M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $7.20M 10-Q · filed 2024-11-07 | $11.15M derived: sum of 2 quarters · filed 2024-11-07 | $14.11M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.94M 10-Q · filed 2024-11-07 | $6.91M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $2.96M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $8.00M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $2.06M 10-Q · filed 2023-11-02 | $4.12M derived: sum of 2 quarters · filed 2023-11-02 | $5.81M derived: sum of 3 quarters · filed 2023-11-02 | |
| 2022-06-30 | $2.06M 10-Q · filed 2023-11-02 | $3.75M derived: sum of 2 quarters · filed 2023-11-02 | ||
| 2022-03-31 | $1.69M 10-Q · filed 2023-11-02 | |||
| 2021-12-31 | $8.08M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | $2.01M 10-Q · filed 2022-11-07 | $3.98M derived: sum of 2 quarters · filed 2022-11-07 | $5.78M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $1.97M 10-Q · filed 2022-11-07 | $3.77M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $1.79M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $6.89M 10-K · filed 2023-03-16 | |||
| 2020-09-30 | $1.77M 10-Q · filed 2021-11-09 | $3.48M derived: sum of 2 quarters · filed 2021-11-09 | $5.04M derived: sum of 3 quarters · filed 2021-11-09 | |
| 2020-06-30 | $1.71M 10-Q · filed 2021-11-09 | $3.27M derived: sum of 2 quarters · filed 2021-11-09 | ||
| 2020-03-31 | $1.57M 10-Q · filed 2021-11-09 | |||
| 2019-12-31 | $6.08M 10-K · filed 2022-03-10 | |||
| 2019-09-30 | $1.57M 10-Q · filed 2020-11-05 | $3.00M derived: sum of 2 quarters · filed 2020-11-05 | $4.43M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $1.43M 10-Q · filed 2020-11-05 | $2.86M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $1.43M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $6.37M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $1.61M 10-Q · filed 2019-11-06 | $3.16M derived: sum of 2 quarters · filed 2019-11-06 | $4.77M derived: sum of 3 quarters · filed 2019-11-06 | |
| 2018-06-30 | $1.54M 10-Q · filed 2019-11-06 | $3.16M derived: sum of 2 quarters · filed 2019-11-06 | ||
| 2018-03-31 | $1.61M 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | $8.14M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $8.24M 10-K · filed 2019-03-07 | |||
| 2015-12-31 | $8.40M 10-K · filed 2018-03-16 | |||
| 2014-12-31 | $7.66M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $4.43M 10-K · filed 2016-03-10 | |||
| 2012-12-31 | $5.31M 10-K · filed 2015-03-11 | |||
| 2011-12-31 | $15.25M 10-K · filed 2014-03-17 | |||
| 2010-12-31 | $13.72M 10-K · filed 2013-03-15 | |||
| 2009-12-31 | $10.57M 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |